Mark Mcdade News Today

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last […]

Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has received a consensus rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued a report on the stock […]

Shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) have earned a consensus rating of “Buy” from the six brokerages that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued ratings on the stock in the […]

Tourmaline Bio (NASDAQ:TRML – Get Free Report)‘s stock had its “buy” rating restated by Truist Financial in a report issued on Monday, Benzinga reports. They currently have a $74.00 price target on the stock. Truist Financial’s target price would indicate a potential upside of 209.88% from the stock’s current price. Several other equities analysts have […]

Director/Board Member at Rallybio Corp., Discover Ron Hunt's known position history, network and 100 relationships. Find out about his known public assets.

Shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) traded down 7.8% during trading on Tuesday . The stock traded as low as $38.61 and last traded at $39.33. 64,967 shares were traded during mid-day trading, a decline of 73% from the average session volume of 238,561 shares. The stock had previously closed at […]

“It’s hard work, it’s dirty work, but there’s always such a feeling of accomplishment at the end."

Icosavax (NASDAQ:ICVX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Icosavax Inc. is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company’s virus-like particle platform technology involved in developing vaccines against infectious […]

Icosavax (NASDAQ:ICVX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Monday, Zacks.com reports. According to Zacks, “Icosavax Inc. is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company’s virus-like particle platform technology involved in developing vaccines against infectious diseases. […]

Icosavax, Inc. (NASDAQ:ICVX – Get Rating) – William Blair dropped their Q2 2022 earnings estimates for Icosavax in a research note issued to investors on Tuesday, May 17th. William Blair analyst A. Hsieh now anticipates that the company will post earnings of ($0.60) per share for the quarter, down from their prior estimate of ($0.56). […]